Hutton Scott 4

What Happened

• Hutton Scott, President & CEO and a director of Biodesix, converted/ exercised 4,844 RSUs into common shares on Feb 20, 2026 (transaction code M). Following the vesting/conversion, 1,490 shares were sold in the open market on Feb 23, 2026 for a weighted average price of $12.78, generating $19,036. The conversion/sale reflects RSU vesting and subsequent tax-withholding sales rather than an independent market purchase.

Key Details

• Transaction dates: conversion/exercise 2026-02-20; sale 2026-02-23. Filing date: 2026-02-23 (reporting period 2026-02-20).
• Shares converted/acquired: 4,844 (from RSUs; M = exercise/conversion of a derivative).
• Shares sold: 1,490 at a weighted average price of $12.78 for proceeds of $19,036. Reported sale prices ranged from $12.58 to $13.16; full breakdown is available on request per the filing.
• Tax withholding: the filing notes these shares were sold automatically to cover taxes upon RSU vesting (automatic/withholding sale).
• RSU details: each RSU equals one share; these RSUs vest in four equal annual installments beginning Feb 20, 2025 and have no expiration. Numbers were adjusted for a 1-for-20 reverse split effective Sep 15, 2025.
• Shares owned after the transaction: not disclosed in the filing.

Context

• This was not a market buy (which can be a bullish signal) but an automatic sale tied to RSU vesting and tax withholding. For derivative items: "exercised/converted" here means previously granted RSUs became actual shares, and a portion was sold to satisfy tax obligations. The reported weighted average sale price and range reflect multiple trades executed by the issuer’s broker to cover withholding.